Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy.

Zeng, Tianmei; Zhou, Lili; Xi, Hao; Fu, Weijun; Du, Juan; Zhang, Chunyang; Jiang, Hua; Hou, Jian.

Afiliação

Zeng T; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
Zhou L; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
Xi H; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
Fu W; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
Du J; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
Zhang C; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
Jiang H; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
Hou J; Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.

Stem Cells Int ; 2015: 613045, 2015.

Article em En | MEDLINE | ID: mdl-25688273

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article